Flipping the odds of drug development success through human genomics
Aroon Dinesh Hingorani, Valerie Kuan, Chris Finan, Felix Alexander Krüger, Anna Gaulton, Sandesh Chopade, Reecha Sofat, Raymond J. MacAllister, John P. Overington, Harry Hemingway, Spiros Denaxas, David Prieto‐Merino, Juan Pablo Casas · bioRxiv (Cold Spring Harbor Laboratory) · 2017
Abstract Drug development depends on accurately identifying molecular targets that both play a causal role in a disease and are amenable to pharmacological action by small molecule drugs or bio-therapeutics, such as monoclonal antibodies. Errors in drug target specification contribute to the extremely high rates of drug development failure. Integrating knowledge of genes that encode druggable targets with those that influence susceptibility to common disease has the potential to radically improve the probability of drug development success.